MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Search

Boston Scientific Corp.

Deschisă

SectorSănătate

91.49 -0.27

Rezumat

Modificarea prețului

24h

Curent

Minim

90.93

Maxim

92.26

Indicatori cheie

By Trading Economics

Venit

-40M

755M

Vânzări

4M

5.1B

P/E

Medie Sector

47.096

89.037

EPS

0.75

Marjă de profit

14.906

Angajați

53,000

EBITDA

-341M

1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+36.46% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-18B

131B

Deschiderea anterioară

91.76

Închiderea anterioară

91.49

Sentimentul știrilor

By Acuity

35%

65%

126 / 360 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Boston Scientific Corp. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 ian. 2026, 13:29 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 ian. 2026, 12:35 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 ian. 2026, 12:29 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

22 oct. 2025, 11:00 UTC

Câștiguri

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

15 ian. 2026, 14:37 UTC

Acțiuni populare

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 ian. 2026, 13:45 UTC

Achiziții, Fuziuni, Preluări

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 ian. 2026, 12:04 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 ian. 2026, 12:03 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 ian. 2026, 12:01 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 ian. 2026, 12:00 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 ian. 2026, 12:00 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

12 ian. 2026, 12:04 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

12 ian. 2026, 12:04 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Specific Terms of Valencia Transaction Not Disclosed >BSX

12 ian. 2026, 12:03 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Valencia Focused on Development of Solutions to Treat Bladder Dysfunction >BSX

12 ian. 2026, 12:00 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Announces Agreement To Acquire Valencia Technologies Corporation >BSX

18 nov. 2025, 17:06 UTC

Câștiguri

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18 nov. 2025, 12:01 UTC

Câștiguri

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

30 oct. 2025, 12:38 UTC

Câștiguri

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

30 oct. 2025, 12:01 UTC

Câștiguri

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

22 oct. 2025, 10:32 UTC

Câștiguri

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 oct. 2025, 10:32 UTC

Câștiguri

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 oct. 2025, 10:31 UTC

Câștiguri

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 oct. 2025, 10:31 UTC

Câștiguri

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific 3Q Adj EPS 75c >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific 3Q Sales $5.07B >BSX

22 oct. 2025, 10:30 UTC

Câștiguri

Boston Scientific 3Q EPS 51c >BSX

Comparație

Modificare preț

Boston Scientific Corp. Așteptări

Obiectiv de preț

By TipRanks

36.46% sus

Prognoză pe 12 luni

Medie 124.45 USD  36.46%

Maxim 140 USD

Minim 100 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBoston Scientific Corp. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

21 ratings

21

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

102.95 / 104.93Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

126 / 360 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat